Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only


| Attribute | ||
|---|---|---|
Research Summary | Melatonin is the "time to sleep" signal. When it gets dark, your brain releases it to tell your entire body to power down, get sleepy, and stay asleep through the night. | DSIP stands for Delta Sleep-Inducing Peptide. It acts like a natural lullaby for your brain, helping you fall into the deepest, most restful stage of sleep without feeling groggy the next morning. |
Studied For | Sleep onset / insomniaCircadian rhythm entrainmentJet-lag disordersShift work sleep disorderAntioxidant / neuroprotection researchAnti-aging / longevityImmune system modulationCancer adjuvant researchAlzheimer's / neurodegeneration modelsSepsis / intensive care researchGastrointestinal motilityMitochondrial protectionBlood pressure regulationSeasonal affective disorder (SAD) researchPediatric sleep disordersDelayed sleep phase syndromeREM behavior disordersleepcircadian rhythmantioxidantjet laginsomnia | Sleep researchDelta-wave sleep promotionSleep onset latency reductionInsomnia researchStress modulationHPA axis regulationHypothalamic regulationCortisol regulationPain modulationOpiate withdrawal researchCircadian rhythm supportAntioxidant neuroprotectionNeuropeptide signaling researchLH/GH sleep pulsatilityREM sleep researchSleep architecture optimizationdeep sleepinsomniastress reductionsleep qualitypain reliefLH regulation |
Research Areas | Sleep & CircadianLongevityImmuneCognitiveMitochondrial Function | Sleep & CircadianCognitiveImmuneLongevity |
Best Stacked With | dsipepithalonpinealonselankbac-water | melatoninselankpinealonbac-water |
Overview | ||
Category | Anti-Aging & Longevity | Immunity & Wellness |
Compound Class | Endogenous indoleamine neurohormone produced by the pineal gland | Endogenous neuropeptide (9 amino acids) produced in hypothalamus |
Molecular Target | MT1 and MT2 melatonin receptors (MTNR1A/MTNR1B); ROR nuclear receptors; ROS scavenging; mitochondrial membrane stabilization | Hypothalamic receptors; modulates GH, LH, corticosteroid release; delta-wave EEG promotion |
Aliases / AKA | N-acetyl-5-methoxytryptamineMelatonin hormonePineal hormoneMelMelatolCircadin | Delta Sleep-Inducing PeptideDSIP peptideDelta sleep peptideDSIP neuropeptideTrp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluSleep peptide |
Parent Compound | Pineal hormone | Endogenous neuropeptide |
Molecular Weight | 232.28 Da | 848.8 Da |
Amino Acid Sequence | N-acetyl-5-methoxytryptamine | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
CAS Number | 73-31-4 | 62568-57-4 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 48,436 Extensive | 545 Good |
Clinical Trials | 516516 Active | 4444 Active |
Regulatory Status | US and Canada: over-the-counter (supplement / natural health product). UK, Australia, and parts of the EU: prescription for licensed insomnia formulations. | Not approved anywhere; research chemical. |
Evidence & Regulatory | ||
Half-Life | ~20-50 min (IR) | ~15 minutes |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Human meta-analyses show a modest reduction in sleep-onset latency and reliable circadian phase-shifting. Oncology and neuroprotective human data are preliminary. | Animal studies report EEG delta induction and anti-stress effects. Human data are limited, dated, and inconsistently reproduced. Weak. |
Side Effects Noted | Low toxicity; daytime drowsiness, headache, dizziness, nausea, vivid dreams. US over-the-counter products are frequently mislabeled. | Sparse safety data; reportedly low toxicity in early work; poorly characterized. |
Warnings | Interacts with anticoagulants, immunosuppressants, antihypertensives, and CYP1A2 drugs. Timing matters; wrong-time dosing can shift the clock the wrong way. | Unconfirmed mechanism and no robust modern trials; rapidly degraded. Research use only. |
Pharmacology | ||
Form | powder or solution | lyophilized |
Diluent | co-solvent required (lipophilic) | bacteriostatic or sterile water |
Storage Temp | cool, dry, dark | frozen, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | n/a | avoid |
Handling Notes | Short half-life ~20-50 min. | Very low metabolic stability; in-vitro half-life around 15 minutes. |
Reconstituted Shelf Life | 14 Days Refrigerated | 14 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Single BPC-157 versus the combined BPC-157 and TB-500 blend in recovery research.
Ipamorelin alone versus the CJC-1295 and ipamorelin blend on the growth-hormone axis.
A synthetic ACTH-fragment nootropic versus a neurotrophic peptide preparation in cognitive research.
Two sleep-research compounds with distinct mechanisms.
A copper tripeptide versus an acetyl hexapeptide in cosmetic and skin research.
A senolytic peptide versus a telomerase-pathway peptide in longevity research.
Two metabolic research compounds targeting the AMPK and NNMT pathways.
A GHRH analog versus an HGH fragment in fat-metabolism research.
Two AMPK-associated mitochondrial and metabolic research compounds.
Two peptides studied for tissue protection and repair.
Two peptides studied for immune and inflammatory modulation.
Two peptide bioregulators studied in longevity and neuro research.
A glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.